Status In progress
Process STA pre-2018
ID number 974

Project Team

Project lead Jeremy Powell

Email enquiries

Consultees

Companies sponsors Janssen
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Bloodwise
  Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Myeloma Forum

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Amgen (carfilzomib)
  Celgene (lenalidomide and pomalidomide)
  Concordia International (dexamethasone)
  Dr Reddy’s Laboratories (bendamustine) (not participating)
  Janssen (bortezomib, daratumumab and doxorubicin)
  Medac UK (bendamustine, doxorubicin) (not participating)
  Napp Pharmaceuticals (bendamustine) (not participating)
  Novartis (panobinostat)
  Zentiva (bendamustine) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Bloodwise
  Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
12 July 2018 - 02 August 2018 Appraisal consultation: 1
06 June 2018 Committee meeting: 1
03 January 2018 Invitation to participate
02 August 2016 - 31 August 2016 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
08 June 2016 Referral
08 June 2016 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance